✦ LIBER ✦

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

✍ Scribed by David Cella; Lesley J. Fallowfield

Publisher: Springer US
Year: 2007
Tongue: English
Weight: 223 KB
Volume: 107
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-007-9548-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug switch because of treatment-related

Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

✍ Uwe Güth; Mary Elizabeth Myrick; Andreas Schötzau; Nerbil Kilic; Seraina Margare 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 199 KB

Practical guidelines for the management

Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion

✍ Axel Hauschild; Helen Gogas; Ahmad Tarhini; Mark R. Middleton; Alessandro Testor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract Interferon‐α‐2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from t

Persistence of bone marrow micrometastas

Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years

✍ Martin J. Slade; Anjana Singh; Brendan M. Smith; Gopi Tripuraneni; Emma Hall; Cl 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 108 KB

We have previously developed a quantitative PCR (QPCR) technique for the detection of cytokeratin 19 (CK19) transcripts in blood and bone marrow and compared this to immunocytochemistry (ICC). Together, both have shown promise for monitoring therapeutic efficacy in patients with metastatic breast ca

Is adjuvant chemotherapy of benefit for

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93

✍ Olivia Pagani; Shari Gelber; Edda Simoncini; Monica Castiglione-Gertsch; Karen N 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 281 KB

Toremifene is an effective and safe alte

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials

✍ Wen-Bin Zhou; Qiang Ding; Ling Chen; Xiao-An Liu; Shui Wang 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 375 KB

The impact of tumor progesterone recepto

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer : A decision analysis

✍ Rinaa S. Punglia; Karen M. Kuntz; Eric P. Winer; Jane C. Weeks; Harold J. Burste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views